Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
FDA Approves Type 2 Diabetes Drug
New combo medication helps control blood glucose
Indications: Synjardy (empagliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin.
Dosing: Individualize the starting dose based on patient’s current regimen. Maximum recommended dose is 12.5 mg empagliflozin/1000 mg metformin twice daily. Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.
Pharmacokinetics: The results of a bioequivalence study in healthy subjects demonstrated that Synjardy (empagliflozin/metformin hydrochloride) 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg combination tablets are bioequivalent to co-administration of corresponding doses of empagliflozin and metformin as individual tablets.
Side Effects/Risks: Assess renal function before initiating. Most common adverse reactions associated with empagliflozin are urinary tract infection and female genital mycotic infections. Adverse reactions with metformin include diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.
Citation: Highlights of prescribing information: Synjardy (empagliflozin and metformin hydrochloride). Prescribing Information, including Medication Guide. Revised August 2015. Accessed August 31, 2015.
This Week's Must Reads
Must Reads in Diabetes
Testosterone Therapy to Prevent T2D in Men, Diabetes Care; ePub 2019 Mar 18; Yassin, et al
Patterns of Diabetes Screening During Office Visits, J Am Board Fam Med; 2019 Mar-Apr; Shealy, et al